Ionis Pharmaceuticals INC 8-K/A Filing
Ticker: IONS · Form: 8-K/A · Filed: Nov 3, 2025 · CIK: 874015
Sentiment: neutral
Filing Stats: 663 words · 3 min read · ~2 pages · Grade level 10.9 · Accepted 2025-11-03 17:17:44
Key Financial Figures
- $300,000 — , Dr. Geary will receive a total fee of $300,000. If Dr. Geary performs more than 16 hou
- $400 — mpany will pay Dr. Geary at the rate of $400 per hour for such additional hours abov
- $450,000 — to Dr. Geary under the Agreement exceed $450,000 without the Company's prior written aut
Filing Documents
- ef20058178_8ka.htm (8-K/A) — 28KB
- ef20058178_ex10-1.htm (EX-10.1) — 107KB
- image0.jpg (GRAPHIC) — 307KB
- image1.jpg (GRAPHIC) — 310KB
- image2.jpg (GRAPHIC) — 330KB
- image3.jpg (GRAPHIC) — 370KB
- image4.jpg (GRAPHIC) — 149KB
- 0001140361-25-040220.txt ( ) — 2302KB
- ions-20251028.xsd (EX-101.SCH) — 4KB
- ions-20251028_lab.xml (EX-101.LAB) — 21KB
- ions-20251028_pre.xml (EX-101.PRE) — 16KB
- ef20058178_8ka_htm.xml (XML) — 4KB
01
Item 1.01 Entry Into a Material Definitive Agreement On October 28, 2025, Ionis Pharmaceuticals, Inc. (the " Company ") and Richard Geary entered into an Advisory Services Agreement (the " Agreement ") pursuant to which Dr. Geary will provide advisory services to the Company following his retirement from the Company in January 2026. The term of the Agreement will begin on January 16, 2026, and will continue through February 13, 2027 (the " Advisory Period "), but may be terminated earlier by either party with at least 15 days' advance written notice Under the Agreement, Dr. Geary will receive a total fee of $300,000. If Dr. Geary performs more than 16 hours of advisory services in any calendar week during the Advisory Period, the Company will pay Dr. Geary at the rate of $400 per hour for such additional hours above 16, up to a maximum of six additional hours in any week during the Advisory Period. In no event will the total amount paid by Company to Dr. Geary under the Agreement exceed $450,000 without the Company's prior written authorization The foregoing summary of the Agreement does not purport to be complete and is qualified in its entirety by reference to the Agreement, which is attached hereto as Exhibit 10.1 and incorporated herein by reference.
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 10.1 Advisory Services Agreement between the Registrant and MedDev Insights LLC for the services of Richard Geary dated January 16, 2026. Portions of this exhibit have been omitted because they are both (i) not material and (ii) the type that the Registrant treats as private or confidential. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Ionis Pharmaceuticals, Inc. Dated: November 3, 2025 By: /s/ Patrick R. O'Neil Patrick R. O'Neil Executive Vice President, Chief Legal Officer and General Counsel